AVXL vs. MLTX, MTSR, VKTX, MOR, KYMR, ALVO, IMVT, CRNX, CPRX, and HCM
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), MorphoSys (MOR), Kymera Therapeutics (KYMR), Alvotech (ALVO), Immunovant (IMVT), Crinetics Pharmaceuticals (CRNX), Catalyst Pharmaceuticals (CPRX), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
Anavex Life Sciences vs. Its Competitors
MoonLake Immunotherapeutics (NASDAQ:MLTX) and Anavex Life Sciences (NASDAQ:AVXL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.
93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
MoonLake Immunotherapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.
In the previous week, Anavex Life Sciences had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 4 mentions for Anavex Life Sciences and 3 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.82 beat Anavex Life Sciences' score of 0.45 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.
MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.
MoonLake Immunotherapeutics' return on equity of -30.81% beat Anavex Life Sciences' return on equity.
MoonLake Immunotherapeutics currently has a consensus price target of $74.50, suggesting a potential upside of 60.68%. Anavex Life Sciences has a consensus price target of $44.00, suggesting a potential upside of 310.45%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than MoonLake Immunotherapeutics.
Summary
MoonLake Immunotherapeutics and Anavex Life Sciences tied by winning 7 of the 14 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:AVXL) was last updated on 7/6/2025 by MarketBeat.com Staff
Free AVXL Stock Alerts